What’s the current market cap for Pacific Biosciences stock?

Pacific Biosciences (PACB) has a market cap of $410m as of June 16, 2026.

What is the P/E ratio for Pacific Biosciences stock?

The price to earnings (P/E) ratio for Pacific Biosciences (PACB) stock is 0 as of June 16, 2026.

Does Pacific Biosciences stock pay dividends?

No, Pacific Biosciences (PACB) stock does not pay dividends to its shareholders as of June 16, 2026.

When is the next Pacific Biosciences dividend payment date?

Pacific Biosciences (PACB) stock does not pay dividends to its shareholders.

What is the beta indicator for Pacific Biosciences?

Pacific Biosciences (PACB) has a beta rating of 2.4. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.

Buy Pacific Biosciences stock | $PACB Share Price

13:30

15:10

16:45

18:25

20:00

About Pacific Biosciences

Pacific Biosciences of California Inc is a biotechnology company focused on designing, developing, and manufacturing sequencing solutions that enable scientists and clinical researchers to improve their understanding of the genome and ultimately, resolve genetically complex problems. It operates in, one reportable segment: the development, manufacturing, and marketing of an integrated platform for genetic analysis. The majority of the company's revenue is derived from Americas, followed by Europe Middle East, and Africa and Asia-Pacific.

Ticker

$PACB

Sector

Health

Primary listing

NASDAQ

Employees

485

Headquarters

Menlo Park, United States

Website

www.pacb.com

PACB Metrics

BasicAdvanced

$410m

-$0.43

2.40

What the Analysts think about PACB

Analyst ratings (Buy, Hold, Sell) for Pacific Biosciences stock.

Bulls say / Bears say

Pacific Biosciences’ preliminary Q4 2025 revenue rose 14% YoY to $44.6 million, driven by strong Revio and Vega system placements and record consumable sales. (Reuters)

In Q1 2026, consumable revenue hit a record $21.8 million, up 9% YoY, underscoring growing pull-through and increasing clinical adoption of HiFi sequencing. (Investing.com)

PacBio was selected by Basecamp Research to power its Trillion Gene Atlas initiative, expected to generate ~100 000 deeply sequenced samples from over 31 countries, cementing its platform’s appeal for large-scale metagenomic projects. (ChartMill)

Q1 2026 total revenue was flat at $37.2 million, unchanged YoY, indicating a lack of top-line growth and potential market saturation. (Stocktitan)

Instrument revenue declined 12% YoY to $9.7 million in Q1 2026, reflecting weaker instrument demand amid academic and government funding pressures. (Yahoo Finance)

PacBio’s cash balance fell by ~$67 million in Q1 2026 to $276 million, raising concerns about cash runway given ongoing net losses. (GlobeNewswire)

Data summarised monthly by Lightyear AI. Last updated on 16 Jun 2026.

PACB Financial Performance

Revenues and expenses

QuarterlyAnnual

Q3 24

QoQ growth

Revenue

$37bn

-39.75%

Net income

$45bn

107.52%

Profit margin

37.65%

6.78%

PACB Earnings Performance

Company profitability

QuarterlyAnnual

Q4 23

Q1 24

Q2 24

Q3 24

Q4 24

Actual

$3.69

$2.85

$2.45

$2.42

Expected

$3.55

$2.61

$2.05

$2.31

$3.94

Surprise

3.94%

9.20%

19.51%

4.63%

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.

Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $PACB

Capital at risk

Market closed

Upcoming events

No upcoming events